Sarcopenia negatively affects the prognosis of chronic diseases. However, the importance of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) has been less emphasized. The aim of the study is to determine the prevalence of sarcopenia in patients with IPF and to evaluate the impact of sarcopenia on quality of life and disease progression. This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Hand Grip Strength
Timeframe: through study completion, an average of 1 year
SMI (skeletal muscle mass index)
Timeframe: through study completion, an average of 1 year
Forced Expiratory Volume in 1 second (FEV1)
Timeframe: through study completion, an average of 1 year
Forced Vital Capacity (FVC)
Timeframe: through study completion, an average of 1 year
Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO)
Timeframe: through study completion, an average of 1 year
Total Lung Capacity (TLC)
Timeframe: through study completion, an average of 1 year
Respiratory Muscle Strength
Timeframe: through study completion, an average of 1 year
Six Minute Walk Test (6MWT)
Timeframe: through study completion, an average of 1 year
Gait speed
Timeframe: through study completion, an average of 1 year
St. George's Respiratory Questionnaire (SGRQ)
Timeframe: through study completion, an average of 1 year
Progressive Disease
Timeframe: through study completion, an average of 1 year